Beraprost sodium, a prostacyclin analog, is a stable and orally active proagent of PGI2 . Beraprost sodium is a potent vasodilator , has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation In Vitro Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity. Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Beraprost sodium (oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6-8-week-old C57Bl/6J Male Mice Dosage: 0.6 mg/kg Administration: Oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days Result: Mitigated the development of renal interstitial fibrosis. Form:Solid IC50& Target:IP